Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
19
Not yet recruiting, industry sponsors, Infectious disease and vaccines, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,856
19 trials
Showing 1 to 19, recently updated first.
- A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older AdultsPivotal-lookingNot yet recruiting
PfizerPfizer (PFE)
NCT07885956 · 750 participants (planned) · Start Oct 29, 2026 · Primary completion Feb 7, 2029
Drug: RSVpreF (Regimen A); RSVpreF (Regimen B) · For: Respiratory Syncytial Virus (RSV)
Sites: Tempe, Arizona; Dublin, California; Doral, Florida · 13 sites in all
- Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor ResponsePivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07797231 · 930 participants (planned) · Start Nov 2026 · Primary completion Sep 2028
Drug: TQA3605 tablets Placebo; TQA3605 tablets and 4 more · For: Chronic Hepatitis B
Sites: Hefei, China; Wuhu, China; Beijing, China · 76 sites in all
- Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.Pivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07941622 · 720 participants (planned) · Start Dec 28, 2026 · Primary completion Apr 27, 2028
Drug: DTaP-IPV-HB-PRP~T combined vaccine; DTaP-IPV//PRP~T combined vaccine and 1 more · For: Haemophilus Influenzae Type b Immunisation; Hepatitis B Immunisation; Polio Immunization and 4 more
- A Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate VaccinePivotal-lookingNot yet recruiting
Reinovax Biologics Co., LTDIndustry
NCT07943585 · 1,260 participants (planned) · Start Nov 24, 2026 · Primary completion Oct 2027
Drug: Prevention of pneumococcal disease from 24 serotypes with the administration of Reinovax's PCV24; PPSV23 · For: Pneumococcal Infectious Disease
Sites: Changsha, China; Baoshan, China; Shanghai, China
- A Study of Ceftobiprole Compared With Standard Antibiotic Treatment in Children With Staphylococcus Aureus Bacteremia (SAB) Infection, Including Right-sided Heart InfectionPivotal-lookingNot yet recruiting
ISTx, LLCIndustry
NCT07929493 · 60 participants (planned) · Start Oct 30, 2026 · Primary completion Oct 31, 2028
Drug: Ceftobiprole medocaril sodium; Standard of Care (SOC) · For: Staphylococcus Aureus Bacteremia; Endocarditis, Bacterial
- A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and OlderPivotal-lookingNot yet recruiting
Guangzhou Patronus Biotech Co., Ltd.Industry
NCT07908654 · 25,000 participants (planned) · Start Nov 2026 · Primary completion Sep 2027
Drug: LYB005; Placebo · For: Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus (RSV) Infection; RSV Vaccine
Sites: Nanjing, China
- Study Interchangeability Hep-B Vaccine Administered at Birth DosePivotal-lookingNot yet recruiting
PT Bio FarmaIndustry
NCT07854847 · 270 participants (planned) · Start Oct 2026 · Primary completion Feb 2027
Drug: In-house Hepatitis B Vaccine; Registered Hepatitis B Vaccine · For: Vaccination Adverse Event; Immunogenicity, Vaccine
- Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.Pivotal-lookingNot yet recruiting
Nanjing Zenshine PharmaceuticalsIndustry
NCT07730346 · 858 participants (planned) · Start Nov 7, 2026 · Primary completion Dec 31, 2027
Drug: Sebaloxavir marboxil; Placebo · For: Influenza Prevention
Sites: Beijing, China
- A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVIDPivotal-lookingNot yet recruiting
HealthBio, Inc.Industry
NCT06974084 · 252 participants (planned) · Start Jul 15, 2026 · Primary completion Dec 1, 2026
Drug: Maraviroc (MVC); Atorvastatin, 10mg, 20mg, 40mg and 2 more · For: Long COVID
Sites: Tucson, Arizona
- A Phase Ⅲ Clinical Study of SNA02-48 InjectionPivotal-lookingNot yet recruiting
Sinovac Life Sciences Co., Ltd.Industry
NCT07633119 · 600 participants (planned) · Start Jun 28, 2026 · Primary completion Mar 31, 2027
Drug: SNA02-48; Human tetanus immunoglobulin (HTIG) · For: Tetanus
Sites: Fuyang, China; Hefei, China; Beijing, China · 30 sites in all
- Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis BPivotal-lookingNot yet recruiting
Fujian Akeylink Biotechnology Co., Ltd.Industry
NCT07588009 · 576 participants (planned) · Start Jun 26, 2026 · Primary completion Jan 11, 2028
Drug: GST-HG141 · For: Chronic Hepatitis b
- Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis BPivotal-lookingNot yet recruiting
Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
NCT07282249 · 630 participants (planned) · Start Dec 31, 2025 · Primary completion Apr 30, 2027
Drug: TVAV-008; PegIFNα2b and 1 more · For: Chronic hepatitisB
- A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID ConditionPivotal-lookingNot yet recruiting
StemCyte, Inc.Industry
NCT07184385 · 60 participants (planned) · Start Mar 31, 2026 · Primary completion Jun 30, 2027
Drug: REGENECYTE; Placebo · For: Long COVID; Post-COVID-19 Condition; Post-COVID Syndrome and 1 more
- Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-VaccinationPivotal-lookingNot yet recruiting
Changchun BCHT Biotechnology Co.Industry
NCT07133802 · 6,680 participants (planned) · Start Aug 2025 · Primary completion Mar 2026
Drug: Placebo Group; Test Group · For: Prevention of Influenza
- A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for SuspensionPivotal-lookingNot yet recruiting
Jiangxi Kvvit Pharmaceutical Co., Ltd.Industry
NCT07113392 · 144 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 1, 2026
Drug: Suraxavir Marboxil; Oseltamivir · For: Influenza
- A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHBPivotal-lookingNot yet recruiting
Shanghai Zhimeng Biopharma, Inc.Industry
NCT07095855 · 1,300 participants (planned) · Start Aug 2025 · Primary completion Jan 2028
Drug: ZM-H1505R 100mg · For: Chronic Hepatitis B
Sites: Changchun, China
- Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)Pivotal-lookingNot yet recruiting
PT Bio FarmaIndustry
NCT05482295 · 540 participants (planned) · Start Sep 2025 · Primary completion May 2026
Drug: In-House Recombinant Hepatitis B (Bio Farma) vaccine; Registered Hepatitis B vaccine recombinant (Engerix-B) · For: Vaccine Reaction; Vaccine Adverse Reaction
- Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and InfluenzaPivotal-lookingNot yet recruiting
Azidus BrasilIndustry
NCT06817096 · 340 participants (planned) · Start Feb 2025 · Primary completion Dec 2026
Drug: Nitazoxanide 600Mg Oral Tablet / placebo oral tablet · For: Covid 19; Influenza
- To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19Pivotal-lookingNot yet recruiting
Sinocelltech Ltd.Industry
NCT04709328 · 690 participants (planned) · Start Mar 28, 2021 · Primary completion Jan 1, 2022
Drug: SCTA01 · For: COVID-19; SARS-CoV-2
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.